Day One Biopharmaceuticals, Inc. financial data

Symbol
DAWN on Nasdaq
Industry
Pharmaceutical Preparations
Location
2000 Sierra Point Parkway, Suite 501, Brisbane, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Day One Biopharmaceuticals Holding Co LLC (to 5/26/2021)
Latest financial report
10-Q - Q3 2024 - Oct 30, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 864 %
Debt-to-equity 13.2 % +113%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 101M shares +15.9%
Common Stock, Shares, Outstanding 101M shares +15.8%
Entity Public Float 759M USD +8.68%
Common Stock, Value, Issued 10K USD +11.1%
Weighted Average Number of Shares Outstanding, Basic 96.6M shares +12.4%
Weighted Average Number of Shares Outstanding, Diluted 96.9M shares +12.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 93.8M USD
Research and Development Expense 203M USD +70.5%
General and Administrative Expense 108M USD +53.9%
Operating Income (Loss) -211M USD -11.7%
Nonoperating Income (Expense) 6.52M USD +23.3%
Income Tax Expense (Benefit) -882K USD
Net Income (Loss) Attributable to Parent 37M USD
Earnings Per Share, Basic -1.02 USD/shares +55.7%
Earnings Per Share, Diluted -1.02 USD/shares +55.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 423M USD +75.3%
Inventory, Net 2.74M USD
Other Assets, Current 322M USD +20.6%
Assets, Current 581M USD +40.6%
Property, Plant and Equipment, Net 904K USD +324%
Operating Lease, Right-of-Use Asset 2.57M USD +482%
Assets 601M USD +45.1%
Accounts Payable, Current 3.02M USD -11%
Accrued Liabilities, Current 16M USD +138%
Liabilities, Current 39.7M USD +62.4%
Operating Lease, Liability, Noncurrent 2.54M USD +3196%
Liabilities 45.3M USD +84.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -6K USD +14.3%
Retained Earnings (Accumulated Deficit) -488M USD -20.9%
Stockholders' Equity Attributable to Parent 555M USD +42.6%
Liabilities and Equity 601M USD +45.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -49.7M USD -91.4%
Net Cash Provided by (Used in) Financing Activities 1.18M USD
Net Cash Provided by (Used in) Investing Activities 89.3M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 101M shares +15.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 423M USD +75.3%
Deferred Tax Assets, Valuation Allowance 94.4M USD +75.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Cash and Cash Equivalents, Period Increase (Decrease) -21.6M USD -119%
Deferred Tax Assets, Gross 94.5M USD +75.1%
Operating Lease, Liability 2.62M USD +409%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -84.3M USD +51.6%
Lessee, Operating Lease, Liability, to be Paid 4.46M USD +727%
Property, Plant and Equipment, Gross 243K USD +106%
Operating Lease, Liability, Current 77K USD -82.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 435K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 352K USD -17%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +44.4%
Deferred Income Tax Expense (Benefit) 900K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.84M USD +7264%
Lessee, Operating Lease, Liability, to be Paid, Year Three 448K USD
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.63M USD +3.91%
Lessee, Operating Lease, Liability, to be Paid, Year Four 461K USD
Operating Lease, Payments 1.1M USD
Additional Paid in Capital 1.04B USD +31.5%
Depreciation, Depletion and Amortization 23K USD +283%
Share-based Payment Arrangement, Expense 48M USD +35.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%